December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Cyclooxygenase-2 (COX-2) is Upregulated in Human Acute Corneal Inflammation
Author Affiliations & Notes
  • EY Tu
    Ophthalmology University of Illinois-Chicago Chicago IL
  • NK Khan
    Pharmacia Corporation St Louis MO
  • D Trajkovic
    Pharmacia Corporation St Louis MO
  • JM Harmon
    Pharmacia Corporation St Louis MO
  • AT Koki
    Pharmacia Corporation St Louis MO
  • M Duffy
    Ophthalmology University of Illinois-Chicago Chicago IL
  • T McMahon
    Ophthalmology University of Illinois-Chicago Chicago IL
  • Footnotes
    Commercial Relationships    E.Y. Tu, Pharmacia F; N.K. Khan, Pharmacia Corporation E; D. Trajkovic, Pharmacia Corporation E; J.M. Harmon, Pharmacia Corporation E; A.T. Koki, Pharmacia Corporation E; M. Duffy, Pharmacia F, C, R; T. McMahon, Pharmacia Corporation F.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 26. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      EY Tu, NK Khan, D Trajkovic, JM Harmon, AT Koki, M Duffy, T McMahon; Cyclooxygenase-2 (COX-2) is Upregulated in Human Acute Corneal Inflammation . Invest. Ophthalmol. Vis. Sci. 2002;43(13):26.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: There are two known isoforms of cyclooxygenase (COX): COX-1 is relatively ubiquitously and constitutively expressed, whereas COX-2 has been shown to be robustly induced in various acute, inflammatory-induced pathologies. COX-2 has been detected in sites of inflammation related to a variety of immune and ulcerative diseases, and COX-2 derived eicosanoids have been implicated in local tissue destruction. Despite the plethora of reports on COX-2 in systemic inflammation, its expression has not been characterized in the normal cornea or inflammatory corneal pathologies. Methods: Appropriate IRB approval was obtained to examine corneal buttons from keratoplasty patients exhibiting both acute and resolved inflammation. All specimens were embedded in paraffin and originated from the University of Illinois-Chicago Eye Center. The six specimens included acute fungal infection (2), autoimmune keratolysis (2), alkali burn with keratolysis (1), and quiescent interstitial keratitis with stromal neovascularization (1). COX-2 expression and distribution was analyzed by immunohistochemical (IHC) analysis in all specimens. Normal human kidneys were utilized as positive controls, and COX-2 was expressed as expected. No appreciable staining was observed in isotype matched-IgG controls. All specimens were read by a licensed pathologist (NK). Results: COX-2 was not detected in normal human corneas. In contrast, COX-2 was strongly expressed in the stroma and epithelium in patients with acute corneal inflammation. COX-2 immunoreactivity in the stroma and epithelium was further detected in ≷80% of patients with clinical keratolysis. Interestingly, COX-2 was not expressed in a patient with post-acute, clinically quiescent interstitial keratitis with chronic, stable neovascularization. Conclusion: In summary, COX-2 is not detected in normal human corneas, or in chronic corneal vascular structures induced by previous inflammation. In contrast, COX-2 is markedly upregulated in acute inflammatory pathologies of the cornea. Importantly, these observations imply COX-2 may play a role in acute inflammatory states in the eye, and may play a role in corneal inflammation associated with clinical necrosis and keratolysis. These data further suggest exploration of the clinical utility of COX-2 to treat acute corneal inflammation may be warranted.

Keywords: 370 cornea: basic science • 437 inflammation • 507 pathology: human 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×